Subsequently, we developed a prognostic risk model based on CDKN1A, KLF2, and IFNG expression that significantly stratifies DLBCL patients into distinct risk groups, thereby potentially informing personalized treatment strategies. This evidence concerns the gene IFNG and diffuse large B-cell lymphoma.